CN118843632A - 噻吩并吡咯并三嗪化合物、其制备及其治疗用途 - Google Patents

噻吩并吡咯并三嗪化合物、其制备及其治疗用途 Download PDF

Info

Publication number
CN118843632A
CN118843632A CN202380021421.XA CN202380021421A CN118843632A CN 118843632 A CN118843632 A CN 118843632A CN 202380021421 A CN202380021421 A CN 202380021421A CN 118843632 A CN118843632 A CN 118843632A
Authority
CN
China
Prior art keywords
acetamide
isopropyl
pyrrolo
oxothieno
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021421.XA
Other languages
English (en)
Chinese (zh)
Inventor
O·阿诺尔德
F·科萨内尔
R·达吉-飞洪
G·兰格特
F·马格特
O·维尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN118843632A publication Critical patent/CN118843632A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380021421.XA 2022-02-21 2023-02-20 噻吩并吡咯并三嗪化合物、其制备及其治疗用途 Pending CN118843632A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22315036.8 2022-02-21
EP22315036 2022-02-21
PCT/EP2023/054138 WO2023156643A1 (en) 2022-02-21 2023-02-20 Thienopyrrolotriazine compounds, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
CN118843632A true CN118843632A (zh) 2024-10-25

Family

ID=81326677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021421.XA Pending CN118843632A (zh) 2022-02-21 2023-02-20 噻吩并吡咯并三嗪化合物、其制备及其治疗用途

Country Status (11)

Country Link
US (1) US20250129091A1 (https=)
EP (1) EP4482841A1 (https=)
JP (1) JP2025506729A (https=)
KR (1) KR20240151767A (https=)
CN (1) CN118843632A (https=)
AU (1) AU2023222186A1 (https=)
CA (1) CA3244475A1 (https=)
CO (1) CO2024010803A2 (https=)
IL (1) IL314781A (https=)
MX (1) MX2024010216A (https=)
WO (1) WO2023156643A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728A (zh) * 2021-12-31 2023-07-04 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210038877A (ko) * 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
JP2023523418A (ja) * 2020-04-23 2023-06-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３の阻害剤としての三環式化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728A (zh) * 2021-12-31 2023-07-04 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途

Also Published As

Publication number Publication date
IL314781A (en) 2024-10-01
KR20240151767A (ko) 2024-10-18
US20250129091A1 (en) 2025-04-24
JP2025506729A (ja) 2025-03-13
MX2024010216A (es) 2024-09-02
CO2024010803A2 (es) 2024-08-20
EP4482841A1 (en) 2025-01-01
CA3244475A1 (en) 2023-08-24
WO2023156643A1 (en) 2023-08-24
AU2023222186A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CN114437105B (zh) 受体相互作用蛋白激酶1的抑制剂
CN103402996B (zh) 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
CN105980378B (zh) 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
CN117510495A (zh) 用于抑制nlrp3的哒嗪化合物
CN105431420B (zh) 二杂芳基化合物及其用途
CN104918934B (zh) 3‑取代的吡唑及其作为dlk抑制剂的用途
CN104159891B (zh) 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
EP2315521B1 (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h 4 receptor
WO2018045911A1 (zh) 二氢嘧啶类化合物及其制备方法和用途
AU2020421426A1 (en) RORγt inhibitor, preparation method thereof and use thereof
WO2025040170A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
CN105658624A (zh) 甲酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JP7417594B2 (ja) Ｔｒｋ阻害剤としてのイミダゾ［１，２－ｂ］ピリダジン
TW202345836A (zh) 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
CN118843632A (zh) 噻吩并吡咯并三嗪化合物、其制备及其治疗用途
CN110049985B (zh) 作为RORγ调节剂的杂环砜类
TWI471327B (zh) 甲基吡咯嘧啶甲醯胺
KR20230083276A (ko) 오토탁신 억제제 화합물
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
CN105829321B (zh) 用于治疗癌症和炎性疾病的化合物
KR20250038236A (ko) 코로나바이러스 감염 치료용 화합물
CN117460718A (zh) 三嗪衍生物及其在癌症的治疗中的用途
TWI753550B (zh) 經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途
BR112020026434A2 (pt) derivados de amino-pirimidonila, um processo para sua preparação e composições farmacêuticas contendo-os
CN117157278A (zh) Nlrp3炎性体的抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination